Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML

Bone Marrow Transplantation

Volumn 48, Issue 8, 2013, Pages 1112-1116

  Deol, A ^a,b   Abrams, J ^b   Masood, A ^a   Al Kadhimi, Z ^a,b   Abidi, M H ^a,b   Ayash, L ^a,b   Lum, L G ^a,b   Ratanatharathorn, V ^a,b   Uberti, J P ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Auto SCT; Plerixafor; Secondary MDS AML; Stem cell mobilization

Indexed keywords

CD34 ANTIGEN; CYCLOSPORIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; PLERIXAFOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPASSIONATE USE; EVENING DOSAGE; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; LEUKOCYTE COUNT; MALE; MORNING DOSAGE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL MOBILIZATION; THROMBOCYTE COUNT;

ADULT; AGED; COMPASSIONATE USE TRIALS; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84881369765     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.10     Document Type: Article

References (25)

1. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502
2. Philip T, Chauvin F, Armitage J, Bron D, Hagenbeek A, Biron P et al. Parma international protocol: Pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood 1991; 77: 1587-1592
3. Allan DS, Keeney M, Howson-Jan K, Popma J, Weir K, Bhatia M et al. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 967-972
4. Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies: Future directions. Bone Marrow Transplant 2009; 43: 181-195
5. Villalon L, Odriozola J, Larana JG, Zamora C, Perez de Oteyza J, Jodra MH et al. Autologous peripheral blood progenitor cell transplantation with o2-10(6) CD34(+)/kg: An analysis of variables concerning mobilisation and engraftment. Hematol J 2000; 1: 374-381
6. De Clercq E. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists. Mol Pharmacol 2000; 57: 833-839
7. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000; 44: 1667-1673
8. Liles WC, Rodger E, Broxmeyer HE, Dehner C, Badel K, Calandra G et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005; 45: 295-300
9. Devine SM, Flomenberg N, Vesole DH, Liesveld J, Weisdorf D, Badel K et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 1095-1102
10. Hubel K, Fresen MM, Salwender H, Basara N, Beier R, Theurich S et al. Plerixafor with and without chemotherapy in poor mobilizers: Results from the German compassionate use program. Bone Marrow Transplant 2011; 46: 1045-1052
11. Duarte RF, Shaw BE, Marin P, Kottaridis P, Ortiz M, Morante C et al. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 2011; 46: 52-58
12. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: Compassionate use data. Bone Marrow Transplant 2008; 41: 331-338
13. Basak GW, Knopinska-Posluszny W, Matuszak M, Kisiel E, Hawrylecka D, Szmigielska-Kaplon A et al. Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience. Ann Hematol 2011; 90: 557-568
14. Darrington DL, Vose JM, Anderson JR, Bierman PJ, Bishop MR, Chan WC et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994; 12: 2527-2534
15. Stone RM, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe SN et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 2535-2542
16. Miller JS, Arthur DC, Litz CE, Neglia JP, Miller WJ, Weisdorf DJ. Myelodysplastic syndrome after autologous bone marrow transplantation: An additional late complication of curative cancer therapy. Blood 1994; 83: 3780-3786
17. Traweek ST, Slovak ML, Nademanee AP, Brynes RK, Niland JC, Forman SJ. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Blood 1994; 84: 957-963
18. Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3128-3135
19. Milligan DW, Ruiz De Elvira MC, Kolb HJ, Goldstone AH, Meloni G, Rohatiner AZ et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: Results from the EBMT. EBMT lymphoma and late effects working parties. European Group for Blood and Marrow Transplantation. Br J Haematol 1999; 106: 1020-1026
20. Krishnan A, Bhatia S, Slovak ML, Arber DA, Niland JC, Nademanee A et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors. Blood 2000; 95: 1588-1593
21. Micallef IN, Lillington DM, Apostolidis J, Amess JA, Neat M, Matthews J et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000; 18: 947-955
22. Traweek ST, Slovak ML, Nademanee AP, Brynes RK, Niland JC, Forman SJ. Myelodysplasia and acute myeloid leukemia occurring after autologous bone marrow transplantation for lymphoma. Leuk Lymphoma 1996; 20: 365-372
23. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatmentrelated myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003; 21: 897-906
24. Li L, Li M, Sun C, Francisco L, Chakraborty S, Sabado M et al. Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/ acute myeloid leukemia and identifies patients at risk. Cancer Cell 2011; 20: 591-605
25. Chakraborty S, Sun CL, Francisco L, Sabado M, Li L, Chang KL et al. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol 2009; 27: 791-798